A federal judge tossed a lawsuit filed in 2010 accusing Medtronic (NYSE:MDT) of violating patents held by W.L. Gore & Associates covering stent graft manufacturing techniques.
Endoscopic
Docs resist prostate test recommendation | MassDevice.com On Call
MASSDEVICE ON CALL — Primary care docs surveyed by Johns Hopkins University researchers say they’re unlikely to curtail their use of a test to detect prostate cancer, despite recommendations from the U.S. Preventive Services Task Force.
The USPSTF stirred up a controversy last year when it suggested that routine prostate-specific antigen tests for healthy men might do more harm than good.
UPDATE: Wall St. reacts to Bard’s $371M win against Gore | Legal News
Updated Feb. 10, 2012, at 1:30 p.m. with share values and analysts’ reactions.
A U.S. federal judge this week upheld C.R. Bard’s (NYSE:BCR) win against W.L. Gore & Associates over vascular graft patents.
Court reaffirms C.R. Bard’s $371M patent win against W.L. Gore | Legal News
A U.S. federal judge this week upheld C.R. Bard’s (NYSE:BCR) win against W.L. Gore & Associates over vascular graft patents.
The court affirmed Bard’s $371 million win from a 2007 decision when an Arizona jury found that Gore willfully infringed on patents for vascular tubing.
Is robotic surgery worth the price? | MassDevice.com On Call
MASSDEVICE ON CALL — Complication rates for women with endometrial cancer were roughly the same after standard laparoscopy and robot-assisted surgery, although the robotic procedures each cost about $1,300 more, according to a study in the Journal of Clinical Oncology.
FDA approves first endovascular grafts for aortic tears | Regulatory Roundup
The FDA granted W.L. Gore & Associates the first U.S. clearance for using an endovascular graft to treat tears or ruptures in the aortic wall.
Gore’s Conformable TAG thoracic endoprosthesis was approved as a treatment for a transection or tear in the aortic wall, an injury typically the result of a car accident, crushing of the chest or a fall from a high place, according to an FDA release.
Report: Olympus files suit against former chairman and 2 execs over accounting scandal
Olympus Corp. (TYO:7733) is taking its former chairman and at least 2 executives to court over the company’s $1.7 billion accounting scandal.
The Japanese endoscopy giant filed suit against former Chairman Tsuyoshi Kikukawa Sunday in Tokyo, The Wall Street Journal reported, citing sources familiar with the situation.
Ex-Olympus CEO Woodford gives up on regaining control, plans to sue
Olympus Corp.’s (TYO:7733) former CEO, Michael Woodford, is abandoning his quest to regain the top seat at the Japanese endoscopy giant, saying he plans to sue for wrongful termination.
Woodford, Olympus’ first and only non-Japanese CEO, was ousted after only 2 weeks on the job after he blew the whistle on a decades-long accounting scandal late last year.
Olympus restates books, takes $1.1B hit | Wall Street Beat
Olympus Corp.’s (TYO:7733) re-stated finances for the past 5 years include a $1.1 billion hit from its 13-year scheme to hide investment losses with specious M&A consulting fees.
The endoscopy giant made the filings with Japanese regulators after being caught red-handed cooking its books to hide the fees, just avoiding a de-listing from the Tokyo stock exchange but fueling rumors that it will need to merge, sell a division or two or raise some cash to keep itself alive.
Smith & Nephew cuts include 24 in Mass.
Recent layoffs at Smith & Nephew (NYSE:SNN) included 24 cuts in Massachusetts, company spokesperson Joe Metzger told MassDevice.
The cuts are part of the British orthopedic giant’s integration of its Andover, Mass.-based endoscopy unit and its Memphis, Tenn.-based orthopedic reconstruction arm.
Layoffs: Smith & Nephew cuts 80 in Memphis orthopedics arm
Smith & Nephew (NYSE:SNN) laid off 80 employees following the merger of its Andover, Mass.-based endoscopy unit and its Memphis, Tenn.-based orthopedic reconstruction unit, according to a report in the Memphis Commercial Appeal.
The British orthopedic giant announced that it would combine the two units in July, alongside the resignation of Memphis-based orthopaedic reconstruction president Joseph DeVivo.